Innovative Therapeutics Alkahest specializes in developing blood-derived therapies for age-related neurological conditions, presenting opportunities to partner or supply in advanced biotech ingredients or clinical services targeting neurodegenerative diseases.

Active Clinical Pipeline With multiple ongoing clinical trials, including Phase 2 studies on Alzheimer’s and immune modulation, there is scope for collaboration in medical devices, assay development, or data analytics to support clinical research and monitoring efforts.

Technological Capabilities Leveraging advanced tech stacks like Tableau, TensorFlow, and Django, Alkahest demonstrates a strong foundation in data-driven research, indicating potential for partnerships in AI, data management, and biotech software solutions.

Financial Growth Potential With recent funding of $50 million and revenue estimates between $10M and $25M, Alkahest is positioned for expansion, offering opportunities in investment, licensing, or strategic partnerships to accelerate their therapy development.

Strategic Acquisition As a subsidiary of Grifols with a history of asset sale and integration, there are collaborative opportunities in joint ventures, supply chain optimization, or distributing their flagship products like GRF6019 to expand market reach.